4.8 Article

A validated clinical tool for the prediction of varices in PBC: The Newcastle Varices in PBC Score

期刊

JOURNAL OF HEPATOLOGY
卷 59, 期 2, 页码 327-335

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2013.04.010

关键词

Liver disease; Chronic; Portal hypertension; Health economics

资金

  1. National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University
  2. NIHR BRC in Ageing and Chronic Disease
  3. BBSRC
  4. MRC
  5. NIHR BRU in Liver Disease
  6. MRC [G0800460, MR/L001489/1] Funding Source: UKRI
  7. Medical Research Council [G0800460, MR/L001489/1] Funding Source: researchfish

向作者/读者索取更多资源

Background 82 Aims: Gastro-oesophageal varices (GOV) can occur in early stage primary biliary cirrhosis (PBC), making it difficult to identify the appropriate time to begin screening with oesophageo-gastro-duodenoscopy (OGD). Our aim was to develop and validate a clinical tool to predict the probability of finding GOV in PBC patients. Methods: A cross-sectional retrospective study analysing clinical data of 330 PBC patients who underwent an OGD at the Freeman Hospital, Newcastle was used to create a predictive tool, the Newcastle Varices in PBC (NVP) Score, that was externally validated in PBC patients from Cambridge (UK) and Toronto (Canada). Results: 48% of the Newcastle, 31% of the Cambridge, and 22% of the Toronto cohorts of PBC patients had GOV. Twenty-five percent (95% CI 18-32%) of the Newcastle cohort had GOV diagnosed at an index variceal bleed. Of the others, 37% (95% CI 28-46%) bled after a median of 1.5 years (IQR 3.75). Transplant-free survival was significantly better in those without GOV than in those with GOV (p <0.001), but similar in patients with GOV that bled and those that did not (p = 0.1). The NVP score (%Probability) = 1/[1 + exp(boolean AND)-(9.186 + 0.001 * alkaline phosphatase in IU - 0.178 * albumin in g/L - 0.015 * platelet x 10(9)) was validated in 2 external cohorts and was highly discriminant (AUROC 0.86). Cost consequences analyses revealed the NVP score to be as accurate as, but more economical than using either OGD directly or other risk scores for screening PBC patients. Conclusions: The NVP score is an inexpensive, non-invasive, externally validated tool that accurately predicts GOV in PBC. (C) 2013 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据